By

Sara Dagen

Lacerta Therapeutics Expands Executive Leadership Team

UF startup Lacerta Therapeutics, a preclinical-stage gene therapy company, announces an expansion in the executive leadership team: illustrating Lacerta’s commitment to developing a constellation of gene-based therapies.

Capri EGM Build-to-Suit Program Acquires Life Science Real Estate Asset for Company Manufacturing Antibodies for Department of Defense and mRNA for COVID-19 Vaccine

UF startup Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the Lab & Research facility, has recently been awarded contract valued as much as $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).